Air-in-Line Alarms During Antineoplastic Drug Infusion (NCT07718711) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Air-in-Line Alarms During Antineoplastic Drug Infusion
Italy40 participantsStarted 2026-07-01
Plain-language summary
The goal of this observational study is to evaluate infusion alarms, particularly air-in-line alarms, during antineoplastic drug infusion in oncology care settings.
The main questions it aims to answer are:
How frequently do infusion alarms occur, and what types of alarms are observed during antineoplastic drug infusion? How long does it take healthcare professionals to manage infusion alarms and restore infusion continuity? What strategies do healthcare professionals use to manage infusion alarms? How do healthcare professionals evaluate the user experience of different infusion technologies?
Participants will be healthcare professionals involved in antineoplastic drug infusion. They will not receive any experimental intervention. Researchers will observe routine infusion procedures and collect data on alarm events, alarm management, infusion technologies, and user experience.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthcare professionals involved in the administration of antineoplastic drugs in participating oncology centres.
* Employment in a participating study site during the study period.
* Direct involvement in routine intravenous antineoplastic drug infusion procedures.
* Participation in infusion procedures eligible for observation according to the study protocol.
Exclusion Criteria:
* Healthcare professionals not directly involved in antineoplastic drug administration.
* Healthcare professionals working outside participating study sites.
* Temporary staff not routinely involved in infusion activities during the observation period.
* Refusal to participate in study activities where local regulations require participant notification.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency and Type of Infusion Alarms
Timeframe: Up to 24 months
Trial details
NCT IDNCT07718711
SponsorAssociazione Italiana Infermieri di Area Oncologica